Compugen Announces Positive Therapeutic Effects of Novel Peptide in Animal Model of Retinopathy
News Jul 23, 2009
Compugen Ltd. has announced that CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway, has shown positive therapeutic effects in an animal model of retinopathy, a very serious eye condition characterized by over-growth of blood vessels.
CGEN-25017, which was initially discovered using Compugen’s Disease-Associated Conformation (DAC) Blockers discovery platform, had previously demonstrated significant inhibitory activity in two other models of angiogenesis, an in vitro multi-cellular assay and the widely recognized chorioallantoic membrane (CAM) model.
In the recently completed study utilizing a rodent model of oxygen-induced retinopathy, administration of CGEN-25017 resulted in a dramatic decrease in the extent of pathological neovascularization, outperforming the positive control, soluble Tie-2. These results provide evidence for the potential use of this novel peptide in the treatment of angiogenic ocular diseases, such as diabetic retinopathy, age-related macular degeneration and retinopathy of prematurity.
Furthermore, since this animal model is well accepted for assessing anti-angiogenic activity in general, the profound dose-dependent anti-angiogenic potency of CGEN-25017 seen in this and earlier studies indicate potential therapeutic utility for other diseases involving pathological angiogenesis such as cancer and inflammatory conditions, including psoriasis and rheumatoid arthritis.
Professor John S. Penn, from the Department of Ophthalmology and Visual Sciences at the Vanderbilt University School of Medicine, who supervised the study and is a recognized world expert in this field stated, “The efficacy achieved with CGEN-25017 is a fairly rare finding in this model. Based upon our past experience conducting efficacy trials of this type, CGEN-25017 falls within the top 10% of all test compounds that have passed through our hands. Thus, in my opinion, CGEN-25017 warrants further development and study as a potential therapy for angiogenesis-related diseases."
Dr. Anat Cohen-Dayag, Compugen co-CEO added, “Angiogenesis is a field of intense research interest worldwide both by academia and industry. CGEN-25017 is a novel peptide that has not only demonstrated very potent anti-angiogenic activity, but it also most likely does so by a different mechanism than known VEGF inhibitors, thus offering the possibility for increased efficacy and fewer side effects. The discovery of CGEN-25017 was made through the use of Compugen’s DAC Blockers platform, which predicts the sequences of novel peptides that may block the folding of certain proteins into their disease-associated states. Peptide blockers predicted by this platform have now been validated experimentally in functional assays for 11 out of 12 protein targets selected for screening.”
Dr. Anat continued, “In addition to CGEN-25017, two other predicted peptides to date have also demonstrated therapeutic potential and several others are now undergoing experimental validation. The DAC Blockers platform itself is one of ten product candidate discovery platforms that have been developed and validated to date by the Company. Thus, the discovery and validation of CGEN-25017 provides an excellent perspective on the power and potential of Compugen’s unique discovery capabilities.”
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018